Forxiga accepted for use within NHS Scotland for chronic heart failure
April 14, 2021Research and Development AstraZeneca, nhs scotland
AstraZeneca have announced that Forxiga (dapagliflozin) has been accepted for use within NHS Scotland by the Scottish Medicines Consortium (SMC) …
BioVersys receives €20 Million EU Financing to develop new antibiotics
April 14, 2021Research and Development EU
The European Investment Bank (EIB) and BioVersys AG, a clinical-stage pharmaceutical company, have today announced the signing of a €20 …
AstraZeneca’s Farxiga falls short in Phase III trials for treatment of COVID-19
April 13, 2021Manufacturing and Production AstraZeneca, COVID-19, covid-19 treatment, farxiga, pharma, pharma news
AstraZeneca’s Farxiga drug, usually used in patients with diabetes, did not show statistical significance in the Phase III trial into …
Regeneron’s drug cocktail shown to prevent symptomatic COVID-19
April 13, 2021Manufacturing and Production COVID-19, REGEN-COV, Regeneron, covid-19 treatment, pharma, pharma news
Regeneron’s REGEN-COV treatment cocktail for COVID-19, a combination between casirivimab and imdevimab, has shown a significant reduction in progression to …
Asthma drug Budesonide helps COVID-19 recovery at home
April 13, 2021Manufacturing and Production COVID-19, asthma drug
Budesonide, a widely-used asthma drug, is the first treatment to be proven to speed up the recovery of COVID-19 patients …
BC Platforms partners with Australian Tissue Bank to improve breast cancer treatment
April 13, 2021Manufacturing and Production Cancer, data
BC Platforms have announced a data partnership with the Australian Breast Cancer Tissue Bank (ABCTB) for its BCRQUEST.com Global Data …
Akari Therapeutics open IND with FDA for bullous pemphigoid treatment
April 13, 2021Manufacturing and Production FDA
Akari Therapeutics have opened an investigational new drug application (IND) with the FDA for its multicentre Phase III study with …
Sanofi to invest €400 million on Singapore vaccine production site
April 12, 2021Sales and Marketing Sanofi, Vaccine
Sanofi have today announced a €400 million investment to create a unique vaccine production centre in Singapore, in partnership with …
EMA launch investigation into J&J’s COVID-19 vaccine amid US blood clot reports
April 12, 2021Sales and Marketing COVID-19, EMA, J&J, JJ, Vaccine
The EMA is reviewing reports of rare blood clots in four people in the US who received Johnson & Johnson’s …
Immutep achieves FDA Fast Track designation for soluble LAG-3 protein
April 12, 2021Sales and Marketing FDA, HNSCC
Immutep, a biotechnology company developing novel immunotherapy treatments for cancer, infectious disease, and autoimmune disease, has achieved FDA Fast Track …
Gynaecologic cancer research collaboration announced
April 12, 2021Sales and Marketing clinical oncology
Context Therapeutics and Integral Molecular have announced a research collaboration and licensing agreement for the development of an anti-claudin 6 …
Immunotherapy combination presented at AACR meeting shows promise in brain cancers
April 12, 2021Sales and Marketing Cancer Conferences | Cancer Conferences 2020 | Oncology Conferences | Oncology Conferences 2020 | International Cancer Conference
Researchers at The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust have found that immunotherapy together with …
Pharmafile.com’s top 10 news stories of the week
April 9, 2021Medical Communications covid 19 news, covid-19 news, news, news roundup, pharma, pharma news
A number of new COVID-19 developments have emerged in April already: AstraZeneca has halted the trial of its COVID-19 vaccine …
Exscientia enter first-ever AI cancer drug into Phase I trials
April 9, 2021Medical Communications AI, Evotec, Exscientia, cancer treatment, oncology, pharma, pharma news
Exscientia and Evotec have announced that they are entering an AI-designed immuno-oncology drug into Phase I trials for the first …
Moderna publishes antibody persistence data of COVID-19 vaccine
April 9, 2021Medical Communications
Moderna have published antibody persistence data out to six months following the second dose of its COVID-19 vaccine (mRNA-1273) in …
Lily and Incyte Phase III COVID-19 study fails to meet primary endpoint
April 9, 2021Medical Communications COVID-19, Eli Lily
Results from Eli Lily and Incyte’s Phase III study, COV-BARRIER, evaluating baricitinib in the treatment of hospitalised COVID-19 patients did …
Abbott receives CE mark approval for TriClip device
April 9, 2021Medical Communications
Abbott have received CE Mark approval for its next-generation TriClip Transcatheter Tricuspid Valve Repair System, the first-of-its-kind tricuspid heart valve …
Novartis MS therapy gains MHRA and EC approval
April 8, 2021European Commission, MHRA, Novartis, pharma, pharma news
The MHRA and European Commission have both granted marketing authorisation to Novartis for its Kesimpta therapy, for the treatment of …
FDA approve Gilead’s breast cancer treatment after Phase III trial
April 8, 2021FDA, Gilead, Trodelvy, pharma, pharma news
The FDA has approved Gilead’s Trodelvy therapy for the treatment of metastatic triple-negative breast cancer (TNBC).
MHRA recommends AstraZeneca jab not be offered to under 30s
April 8, 2021The MHRA have recommended that people under the age of 30 not be offered the AstraZeneca COVID-19 vaccine, due to …
Latest content
Report highlights scope to expand day surgery
Sygnature formalises drug discovery collaboration with X-Chem
Codis appoints Steven Facer as chief commercial officer
Danish medical cannabis use rises as regulator reports no new safety signals
